A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis

NCT04207801 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Plaque-type Psoriasis

Interventions

DRUG: AUR101
DRUG: Matching Placebo

Sponsor

Aurigene Discovery Technologies Limited